BBHC
CORT icon

Brown Brothers Harriman & Co’s Corcept Therapeutics CORT Stock Holding History

Brown Brothers Harriman & Co’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-312
Closed -$12.6K – 1834
2026
Q1 		$12.6K Hold
312
– – ﹤0.01% 1311
2025
Q4 		$10.9K Sell
312
-552
-64% -$43.4K ﹤0.01% 1324
2025
Q3 		$71.8K Buy
864
+707
+450% +$51.2K ﹤0.01% 943
2025
Q2 		$11.5K Hold
157
– – ﹤0.01% 1176
2025
Q1 		$17.9K Hold
157
– – ﹤0.01% 973
2024
Q4 		$7.91K Hold
157
– – ﹤0.01% 1162
2024
Q3 		$7.27K Buy
+157
New +$5.58K ﹤0.01% 1096
2019
Q1 		– Sell
-2,075
Closed -$28K – 1015
2018
Q4 		$28K Buy
+2,075
New +$27.4K ﹤0.01% 589

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Brothers Harriman & Co's CORT Position: Q2 2026 in Review

Brown Brothers Harriman & Co sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 312 shares — an estimated $12.6K sold.

Brown Brothers Harriman & Co first reported a position in CORT in Q4 2018 and held it in 8 quarters. The position peaked at $71.8K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Brown Brothers Harriman & Co reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 312 Corcept Therapeutics shares in Q2 2026, an estimated $12.6K.
  • Brown Brothers Harriman & Co first reported a position in Corcept Therapeutics in Q4 2018 and held it in 8 quarters.
  • Brown Brothers Harriman & Co's Corcept Therapeutics position peaked at $71.8K in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.